Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab
Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab — regulatory update affecting Med-Spa & Aesthetics Clinics.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-Spa & Aesthetics Clinics (nurse-owned, physician-owned, multi-location, new openings) should confirm how it applies to their specific situation before acting. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Med-Spa & Aesthetics Clinics move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab
Who it affects
Med-Spa & Aesthetics Clinics (nurse-owned, physician-owned, multi-location, new openings)
What you must do
Note this update; no immediate action appears required, but monitor for follow-on rules.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial